* Anaphylaxis (Immediate Hypersensitivity): From Old to New Mechanisms * Antiviral Responses * Autophagy and Inflammation * Basophils * Cell signalling in neutrophils * Co-stimulatory Receptors * Dendritic Cells * GILZ-Related Regulation of Inflammation * Glial Cells* Immunoglobulin receptors and inflammation * Inflammatory Bowel Disease Models in Animals * Leukocyte Recruitment * Lymphocyte homing and trafficking * Macrophage Heterogeneity During Inflammation * Mast Cells * Mechanisms of Macrophage Migration in 3-Dimensional Environments * Microvascular Responses to Inflammation * Modulation of Inflammation by Key Nutrients * Natural Killer Cells * Neutrophil Extracellular Traps * Neutrophil oxidative burst * Obesity and Inflammation * Osteoclasts in Inflammation * Platelets, Endothelium, and Inflammation * Sepsis Models in Animals * Skin inflammation models in animals * Th17 Response * Toll-Like Receptors * Angiogenesis Inhibitors * Anti-asthma Drugs, Overview * Anti-histamines * Anti-muscarinics * Antibiotics as anti-inflammatory drugs* Antimalarial Drugs * Beta2 Receptor Agonists * CD20 Inhibitors: Rituximab * CD80/86 Inhibitors: Abatacept * Chromones - Cromoglycate and Nedocromil * Corticosteroids * Coxibs * Disease-Modifying Anti-Rheumatic Drugs: Overview* Fenamates * Flavonoids as Anti-inflammatory Agents * Gold Complexes * Interleukin-1 (IL-1) Inhibitors: Anakinra, Rilonacept, and Canakinumab * Interleukin-12/23 Inhibitors: Ustekinumab * Interleukin-6 Inhibitor - Tocilizumab * Janus Kinase Inhibitors * Leflunomide* Medicinal Fatty Acids * Methotrexate * Non-steroidal anti-inflammatory drugs * Phosphodiesterase 4 Inhibitors -- Apremilast and Roflumilast * Propionic Acid Derivative Drugs (Profens)* Salicylates * Sulfasalazine and Related Drugs * Tetracyclines * Theophylline * Thiopurines: Azathioprine, Mercaptopurine and Thioguanine * Tumor Necrosis Factor (TNF) Inhibitors * Acute Exacerbations of Airway Inflammation * Allergic Disorders* Alzheimer's Disease * Antiphospholipid antibody syndrome * Asthma * Atherosclerosis * Atopic Dermatitis * Autoinflammatory Syndromes * Behcet's Disease * Bronchiolitis obliterans * Cancer and inflammation * Cogan's syndrome <* Diabetes type I* Diabetes type II * Diffuse Panbronchiolitis * Gaucher Disease * Genetic susceptibility to inflammatory diseases * Gout* Granulomatosis with Polyangiitis (GPA) * Graves' Disease * Henoch-Schoenlein Purpura * Idiopathic Thrombocytopenic Purpura * Inflammatory bowel disease * Kawasaki Disease * Osteoarthritis * Osteoarthritis Genetics * Polymyositis and Dermatomyositis * Rheumatic Fever * Rheumatoid arthritis* Role of Cell Therapy in Autoimmune Disease * Sarcoidosis * Sepsis * Spondyloarthritis * ACKR3 * Alarmins * Antibacterial Host Defense Peptides * Bacterial Lipopolysaccharide * Biofilm * Bone Morphogenetic Proteins in Inflammation< * CCR1 * CXCL4 und CXCL4L1 * CXCR1 and CXCR2 and Ligands * CXCR3 and Its Ligands * Ceramide 1-Phosphate: A Mediator of Inflammatory Responses * Chemokine CCL14 * Chemokine CCL15 * Chemokine CCL18 * Complement System * Complement C5a Receptors * Cytokines * Cytolytic Granules * Foxp3 * Heat Shock Proteins* Histamine * IkappaB * Inflammasomes* Interferon gamma * Interleukin 10 * Interleukin 12 * Interleukin 17 * Interleukin 18 * Interleukin 18 Binding Protein * Interleukin 2 * Interleukin 22 * Interleukin 23 * Interleukin 27 * Interleukin 32* Interleukin 36 Cytokines * * Interleukin 6 * Interleukin 9 * Interleukin-33 * Janus Kinases (JAKs)/STAT Pathway * Kinins * Leukotrienes * MAP Kinase Pathways * Mammalian Target of Rapamycin (mTOR) * NFkappaB * Nuclear Receptor Signaling in the Control of Inflammation * Pathogen-Associated Molecular Patterns (PAMPs) * Pentraxins * Prostanoids * Protease-Activated Receptors * Reactive oxygen species * Substance P in Inflammation * TGF-b superfamily cytokine MIC-1/GDF15 in health and inflammatory diseases* TNFalpha * Type I Interferons
Michael Parnham studied pharmacology at London University, UK and obtained his PhD in pharmacology at Bristol University, subsequently performing postdoctoral work in inflammation at Erasmus University Rotterdam, The Netherlands. He is currently Head of Preclinical Research in the Fraunhofer Institute of Molecular Biology & Applied Ecology, Project Group for Translational Medicine & Pharmacology TMP, Frankfurt am Main, Germany and since 1998 has been Adjunct Professor of Pharmacology & Toxicology at Goethe University Frankfurt. He is also a Fellow of the British Pharmacological Society. Prior to his present position, Dr Parnham was Visiting Scientist in the Hospital for Infectious Diseases Zagreb, Croatia and Director of Preclinical Discovery, GlaxoSmithKline, Zagreb. From 1998 to 2006 he was Head of Pharmacology & Toxicology and then Senior Scientific Advisor at PLIVA, Zagreb and was previously employed for a decade by A. Nattermann and subsequently Rhone-Poulenc Sante in Cologne, Germany, where he rose to become Head of General Biology. Dr Parnham has researched and published extensively on inflammatory mediators and mechanisms, anti-inflammatory, antibiotic and immunomodulatory drugs, toxicology and the pharmacology of selenium. He was Managing Editor of the international journal Inflammation Research from 1992 to 2013 and is editor of several book series, including Milestones in Drug Therapy and Progress in Inflammation Research, and the textbook Principles of Immunopharmacology. He has helped discover and develop 6 compounds up to clinical trials, including 2 novel biologicals and a seleno-organic compound, for which he and his group received the Prix Galien Germany in 1990. Dr Parnham has run a pharmaco-toxicological consultancy in Germany for 8 years, has been involved in discussions with EMEA on drug safety and was a representative of the European Generics Association on the working group for biosimilar drugs. In 2015, he received the Lifetime Achievement Award of the International Association of Inflammation Societies.